These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15238369)

  • 1. ALLHAT: setting the record straight.
    Davis BR; Furberg CD; Wright JT; Cutler JA; Whelton P;
    Ann Intern Med; 2004 Jul; 141(1):39-46. PubMed ID: 15238369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 5. ALLHAT, or the soft science of the secondary end point.
    Neely DB
    Ann Intern Med; 2004 Jul; 141(1):77. PubMed ID: 15238380
    [No Abstract]   [Full Text] [Related]  

  • 6. ALLHAT, or the soft science of the secondary end point.
    Messerli FH
    Ann Intern Med; 2003 Nov; 139(9):777-80. PubMed ID: 14597462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A family physician questions the conclusions from ALLHAT.
    Standridge JB
    Am J Hypertens; 2004 Apr; 17(4):361-5. PubMed ID: 15062891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALLHAT: a critical assessment.
    Sjöholm A
    Blood Press; 2004; 13(2):75-9. PubMed ID: 15182109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy.
    Maio V; Gagne JJ
    J Clin Pharm Ther; 2010 Feb; 35(1):55-61. PubMed ID: 20175812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
    Furberg CD; Psaty BM; Pahor M; Alderman MH
    Ann Intern Med; 2001 Dec; 135(12):1074-8. PubMed ID: 11747386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
    Wright JT; Cushman WC; Davis BR; Barzilay J; Colon P; Egan D; Lucente T; Nwachuku C; Pressel S; Leenen FH; Frolkis J; Letterer R; Walsh S; Tobin JN; Deger GE;
    Control Clin Trials; 2001 Dec; 22(6):659-73. PubMed ID: 11738122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for antihypertensive treatment: an update after the ALLHAT study.
    Salvetti A; Ghiadoni L
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S51-4. PubMed ID: 14684673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALLHAT says diuretics are better; ANBP2 says ACEs are better--can we resolve the differences?
    Vidt DG
    Cleve Clin J Med; 2004 Feb; 71(2):145-50. PubMed ID: 14982197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments on the renal aspects of the ALLHAT study.
    Ruilope LM
    J Hypertens; 2003 Feb; 21(2):235-6. PubMed ID: 12569244
    [No Abstract]   [Full Text] [Related]  

  • 19. ALLHAT in perspective: implications to clinical practice and clinical trials.
    Yusoff K
    Med J Malaysia; 2005 Jun; 60(2):239-45. PubMed ID: 16114170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Commentary on the ALLHAT study. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Wehling M
    Dtsch Med Wochenschr; 2003 May; 128(22):1252. PubMed ID: 12772085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.